Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $100

Morgan Stanley maintains Nevro (NYSE:NVRO) with a Overweight and raises the price target from $76 to $100.

Benzinga · 11/07/2019 14:26

Morgan Stanley maintains Nevro (NYSE:NVRO) with a Overweight and raises the price target from $76 to $100.